Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
RA Capital Management and affiliated reporting persons reported beneficial ownership of 2,078,913 shares of Karyopharm Therapeutics common stock, representing 9.99% of the class.
The filing states the Fund directly holds 1,917,354 shares, pre-funded warrants exercisable for 3,391,164 shares, and warrants exercisable for 4,421,518 shares. The filing cites 19,618,032 shares outstanding as of March 23, 2026 and references a private placement of 1,030,354 shares that closed March 26, 2026. The Warrants include "Beneficial Ownership Blockers" that limit exercise to prevent ownership above 9.99%.
Karyopharm Therapeutics Inc. Schedule 13G shows Commodore Capital and related filers report beneficial ownership of 1,950,000 shares of Common Stock, representing 9.9% of the class. The filing states the ownership is based on 19,618,032 shares outstanding as of March 23, 2026.
Karyopharm Therapeutics Inc. completed a private placement with RA Capital Management, selling 1,030,354 common shares at $6.785 each and pre-funded warrants for up to 3,391,164 shares at $6.7849, plus warrants for 4,421,518 shares at a $10.00 exercise price, for gross proceeds of about $30 million.
In March 2026 it also sold 2,994,441 common shares under its at-the-market sales agreement for net proceeds of about $19.8 million. After these transactions, it had 22,543,316 common shares outstanding and pre-funded warrants for 4,005,556 shares, and expects its liquidity to fund operations into late in the third quarter of 2026.
Karyopharm Therapeutics entered a private placement with RA Capital, selling 1,030,354 common shares, 3,391,164 pre-funded warrants, and 4,421,518 common warrants, for about $30 million in gross proceeds, plus about $44 million if all warrants are exercised. In March 2026 it also sold 1,100,844 shares via its at-the-market program for about $9.6 million net, and had 19,618,032 shares outstanding as of March 23, 2026. Closing the private placement will satisfy the capital-raise trigger for its amended credit and forbearance agreements.
The Phase 3 SENTRY myelofibrosis trial met the spleen-volume co-primary endpoint, with 50% of patients on selinexor plus ruxolitinib achieving SVR35 at week 24 versus 28% on ruxolitinib alone, but did not show a statistically significant symptom-score benefit. A nominally significant overall-survival signal was reported with a hazard ratio of 0.43. Safety showed more grade 3+ adverse events (70% vs 50%) and higher discontinuations (15% vs 9%). Karyopharm will seek FDA feedback on a supplemental NDA. The company will voluntarily withdraw the accelerated approval for the DLBCL indication of XPOVIO due to feasibility of completing the confirmatory trial, noting minimal revenue from that use.
Karyopharm Therapeutics entered a private placement with RA Capital, selling 1,030,354 common shares, 3,391,164 pre-funded warrants, and 4,421,518 common warrants, for about $30 million in gross proceeds, plus about $44 million if all warrants are exercised. In March 2026 it also sold 1,100,844 shares via its at-the-market program for about $9.6 million net, and had 19,618,032 shares outstanding as of March 23, 2026. Closing the private placement will satisfy the capital-raise trigger for its amended credit and forbearance agreements.
The Phase 3 SENTRY myelofibrosis trial met the spleen-volume co-primary endpoint, with 50% of patients on selinexor plus ruxolitinib achieving SVR35 at week 24 versus 28% on ruxolitinib alone, but did not show a statistically significant symptom-score benefit. A nominally significant overall-survival signal was reported with a hazard ratio of 0.43. Safety showed more grade 3+ adverse events (70% vs 50%) and higher discontinuations (15% vs 9%). Karyopharm will seek FDA feedback on a supplemental NDA. The company will voluntarily withdraw the accelerated approval for the DLBCL indication of XPOVIO due to feasibility of completing the confirmatory trial, noting minimal revenue from that use.
Karyopharm Therapeutics Inc. executive Mano Michael, EVP, CLO & Secretary, reported an open-market sale of 3,526 shares of common stock at an average price of $9.4095 per share. According to the disclosure, this broker-assisted sale was made under a durable automatic sale instruction plan and was used solely to cover withholding taxes triggered by the vesting of restricted stock units, rather than a discretionary trade. After this tax-related transaction, Michael held 93,964 shares of Karyopharm common stock directly.
Karyopharm Therapeutics EVP & Chief Commercial Officer Sohanya Roshan Cheng reported an open-market sale of 4,604 shares of common stock at $9.4095 per share. This broker-assisted sale was executed under a durable automatic sale instruction plan to cover withholding taxes on vested restricted stock units and was not a discretionary trade. After the transaction, Cheng directly holds 107,317 shares.
Karyopharm Therapeutics Inc. executive Reshma Rangwala, EVP & Chief Medical Officer, reported an open-market sale of 5,066 shares of common stock at an average price of $9.4095 per share. After this transaction, she held 56,739 shares directly.
According to the disclosure, the sale was executed under a pre-established durable automatic sale instruction plan adopted on April 4, 2022. The shares were sold by a broker to cover withholding tax obligations arising from the vesting of restricted stock units, and the filing states that the transaction did not represent a discretionary trade by the reporting person.
Karyopharm Therapeutics Inc. President and CEO Richard A. Paulson reported an automatic sale of common stock under a pre-established durable automatic sale instruction plan. On this transaction date, he sold 12,361 shares of common stock at an average price of $9.4095 per share in a broker-assisted transaction to satisfy withholding tax obligations arising from the vesting of restricted stock units. Following this tax-related, non-discretionary sale, he continued to hold 267,030 shares of Karyopharm Therapeutics common stock directly.
Karyopharm Therapeutics Inc. executive Stuart Poulton, EVP and Chief Development Officer, reported an automatic sale of common stock to cover taxes tied to restricted stock units that vested. On this transaction date, he sold 5,101 shares in an open-market sale at an average price of $9.4095 per share under a durable automatic sale instruction plan adopted on May 18, 2022. The filing states this broker-assisted sale was executed to satisfy withholding tax liabilities and did not represent a discretionary trade by Poulton. Following the sale, he directly held 94,328 shares of Karyopharm common stock.
Karyopharm Therapeutics Inc. Chief Accounting Officer Kristin Abate reported an open-market sale of 559 shares of common stock at an average price of $9.4095 per share. After this transaction, she directly owns 22,063 shares. The sale was executed under a pre-established automatic plan solely to cover tax withholding on vested restricted stock units and was not a discretionary trade.